Transcranial Magnetic Stimulation and Anti-epileptic Effect: Optimization and Evaluation With Electrophysiology.
September 26, 2025 updated by: University Hospital, Strasbourg, France
Epileptic disease is characterised by enhanced brain excitability.
Low frequency repetitive transcranial magnetic stimulation (rTMS) can be an effective treatment for refractory frontal epilepsy.
Thought, physiological mechanisms of its effectivity are still unknown.
It is yet possible to evaluate cortical excitability and inhibition with TMS-coupled electromyography before and after rTMS sessions ; this could provide clues for basic mechanisms of rTMS effects on the epileptic brain.
We assume that rTMS decrease brain excitability by improving brain inhibition.
Such an information could help for treating patients with both pharmacological and non-pharmacological methods.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
15
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Strasbourg, France, 67091
- Département de Neurologie - Hôpital Civil
-
Strasbourg, France, 67091
- Institut de Physique Biologique
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
12 years and older (Child, Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Cryptogenic frontal lobe epilepsy
- Normal cerebral MRI
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
|---|
|
Electrophysiological parameters for cortical excitability measured just before and after rTMS, 4 hours later and 24 hours later.
|
Secondary Outcome Measures
Outcome Measure |
|---|
|
Clinical efficacity on seizure intensity and frequency.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Study Director: Serge CHASSAGNON, MD, Hopitaux Universitaires de Strasbourg
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 1, 2006
Primary Completion (Actual)
September 1, 2009
Study Completion (Actual)
August 1, 2011
Study Registration Dates
First Submitted
September 28, 2006
First Submitted That Met QC Criteria
September 28, 2006
First Posted (Estimated)
September 29, 2006
Study Record Updates
Last Update Posted (Estimated)
October 1, 2025
Last Update Submitted That Met QC Criteria
September 26, 2025
Last Verified
September 1, 2025
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 3540
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.